Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2019-01-23 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Appendix 3B - issue of unlisted share options 13 pages 178.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, exercise price, expiry date, vesting schedule, and other terms. It also includes sections on the quotation of securities on the ASX, warranties to the ASX, and compliance with relevant listing rules. The document is a formal announcement related to the issuance and quotation of additional securities, consistent with regulatory requirements for capital raising disclosures. It does not contain financial statements or management discussion, nor is it a report or transcript. The document fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2019-01-23 English
Detailed Program Update - January 2019 81 pages 5.9MB
Investor Presentation Classification · 95% confidence The document is a detailed program update presentation from Telix Pharmaceuticals Limited dated January 2019. It includes extensive information about the company's clinical pipeline, market metrics, clinical trials, management team, and M&A activity. The content is structured as a presentation with slides, images, and detailed descriptions of products, clinical phases, and strategic plans. There are no financial statements, audit opinions, or regulatory certifications present. The document is not a brief announcement or a short notice but a comprehensive presentation aimed at investors or stakeholders, focusing on company strategy, clinical progress, and market opportunities. This matches the definition of an Investor Presentation (IP).
2019-01-08 English
Update - Acceleration of Prostate Cancer Therapy Program 4 pages 107.1KB
Investor Presentation Classification · 95% confidence The document is titled 'Strategy Update – Acceleration of Prostate Cancer Therapy Program' and dated January 8, 2019. It discusses clinical data audits, Phase III trial planning, regulatory interactions with the FDA, manufacturing plans, and capital requirements related to a prostate cancer therapy program. The content is a detailed strategic update on a specific drug development program, including clinical data analysis and future plans, rather than a formal financial report or regulatory filing. It does not contain financial statements or earnings data, nor is it a transcript of a call or a voting result announcement. It is also not a notice of dividend, share issue, or insider dealing. The document is a corporate announcement providing a strategic update to investors and stakeholders about the progress and plans for a clinical program, which aligns best with an Investor Presentation (IP) category, as it focuses on financial and strategic information relevant to investors. The length (over 11,000 characters) and detailed content support this classification rather than a brief announcement or regulatory filing.
2019-01-07 English
Investor Presentation and Program Update 19 pages 5.1MB
Investor Presentation Classification · 95% confidence The document is an investor introduction presentation for Telix Pharmaceuticals Limited dated January 2019. It contains detailed information about the company's business model, clinical pipeline, market metrics, management team, and M&A activity. The content is structured as a presentation with slides, including forward-looking statements, clinical trial summaries, market opportunities, and corporate strategy. There are no financial statements, audit opinions, or regulatory certifications present. The document is not a formal financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript of a call or a voting result announcement. It is clearly a detailed investor presentation aimed at providing financial and strategic information to investors. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and content support a high confidence in this classification.
2019-01-07 English
Telix Pharmaceuticals Completes Acquisition of ANMI SA 2 pages 205.8KB
M&A Activity Classification · 95% confidence The document is an announcement by Telix Pharmaceuticals Limited about the completion of an acquisition of Advanced Nuclear Medicine Ingredients (ANMI) SA. It details the acquisition terms including share issuance, cash payment, debt assumption, and escrow arrangements. The document does not contain financial statements, quarterly or annual results, or detailed management discussion. It is not a full annual or interim report, nor an earnings release. It is not a regulatory filing or certification. The content focuses on a corporate transaction related to acquisition, which falls under M&A activity. Therefore, the document is best classified as M&A Activity (TAR). The document length is 4446 characters, which is consistent with an announcement rather than a full report.
2018-12-23 English
Cleansing Notice - Issue of Consideration Shares 1
Share Issue/Capital Change Classification · 100% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of shares by Telix Pharmaceuticals Limited without a prospectus. It details the issuance of fully paid ordinary shares and compliance with relevant sections of the Act. The document also references an Appendix 3B, which is typically a form related to capital changes. The content is an announcement of a share issue rather than a full report or financial statement. The document length is short (1187 characters), and it serves as a formal notification of a capital change event. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA).
2018-12-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.